zaleplon has been researched along with Depression in 2 studies
zaleplon: an azabicyclo(4.3.0)nonane; a nonbenzodiazepine; one of the so-called of Z drugs (zopiclone, eszopiclone, zolpidem, and zaleplon) for which there is some correlation with tumors; a hypnotic with less marked effect on psychomotor functions compared to lorazepam
zaleplon : A pyrazolo[1,5-a]pyrimidine having a nitrile group at position 3 and a 3-(N-ethylacetamido)phenyl substituent at the 7-position.
Depression: Depressive states usually of moderate intensity in contrast with MAJOR DEPRESSIVE DISORDER present in neurotic and psychotic disorders.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Major depressive disorder is also highly comorbid in this population, leading to further impairment." | 5.62 | Treatment of Insomnia with Zaleplon in HIV+ Significantly Improves Sleep and Depression. ( Goldschmied, JR; Kayser, MS; Morales, KH; Sengupta, A; Sharma, A; Taylor, L; Thase, ME; Weljie, A, 2021) |
| "Major depressive disorder is also highly comorbid in this population, leading to further impairment." | 1.62 | Treatment of Insomnia with Zaleplon in HIV+ Significantly Improves Sleep and Depression. ( Goldschmied, JR; Kayser, MS; Morales, KH; Sengupta, A; Sharma, A; Taylor, L; Thase, ME; Weljie, A, 2021) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Goldschmied, JR | 1 |
| Sengupta, A | 1 |
| Sharma, A | 1 |
| Taylor, L | 1 |
| Morales, KH | 1 |
| Thase, ME | 2 |
| Weljie, A | 1 |
| Kayser, MS | 1 |
| Belleville, G | 1 |
| Morin, CM | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A 6-week Open-Label Study of Treatment of Insomnia With Zaleplon in HIV Positive Patients With Comorbid Depression[NCT03489304] | Phase 2 | 20 participants (Actual) | Interventional | 2014-04-03 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The Epworth Sleepiness Scale (ESS) is a validated sleep scale that quantifies daytime sleepiness across eight domains. The total score ranges from 0-24 where higher values indicate greater daytime sleepiness. (NCT03489304)
Timeframe: Measure at 6 weeks
| Intervention | score on a scale (Mean) |
|---|---|
| Zaleplon | 6.5 |
The Insomnia Severity Index is a validated sleep scale that measures clinical insomnia severity. The total score ranges from 0-28 where higher values indicate increased severity of insomnia. (NCT03489304)
Timeframe: Measure at 6 weeks
| Intervention | score on a scale (Mean) |
|---|---|
| Zaleplon | 11 |
The Quick Inventory of Depressive Symptomatology (QIDS) is a validated mood scale that quantifies depression symptoms. The total score ranges from 0-48, where higher values indicate greater depressive symptoms. (NCT03489304)
Timeframe: Measure at 6 weeks
| Intervention | score on a scale (Mean) |
|---|---|
| Zaleplon | 8.7 |
1 trial available for zaleplon and Depression
| Article | Year |
|---|---|
Hypnotic discontinuation in chronic insomnia: impact of psychological distress, readiness to change, and self-efficacy.
Topics: Acetamides; Adaptation, Psychological; Adult; Aged; Anxiety; Attitude to Health; Azabicyclo Compound | 2008 |
1 other study available for zaleplon and Depression
| Article | Year |
|---|---|
Treatment of Insomnia with Zaleplon in HIV+ Significantly Improves Sleep and Depression.
Topics: Acetamides; Depression; Depressive Disorder, Major; Humans; Pyrimidines; Quality of Life; Sleep; Sle | 2021 |